现代羟乙基淀粉与心脏手术后急性肾损伤:前瞻性多中心队列研究
该多中心前瞻性队列纳入23家西班牙医院1058例心脏手术患者,350例(33%)术中和术后使用6% HES 130/0.4,377例(36%)发生术后AKI。多变量风险校正后,6% HES 130/0.4使用与AKI风险显著增加无关(校正OR 1.01,95%CI 0.71-1.46,P=0.91),倾向性评分匹配分析证实该结果。
要点
- 心脏手术术中和术后使用6% HES 130/0.4未显著增加术后AKI风险。
- 多变量校正后AKI风险校正OR 1.01(95%CI 0.71-1.46,P=0.91)。
- 倾向性评分匹配分析结果与主分析一致。
核心结论
- 在本多中心队列中,术中和术后使用现代羟乙基淀粉6% HES 130/0.4与心脏手术后AKI及透析风险增加无关。
研究设计与样本
- 前瞻性多中心队列研究,纳入2012年9月15日至12月15日在23家西班牙医院连续接受心脏手术的1058例患者。
主要发现
- 350例(33%)术中和术后使用6% HES 130/0.4,377例(36%)发生术后AKI(AKI Network标准)。
- 院内死亡45例(4.2%)。
- 非HES组Euroscore更高,合并症更多(包括不稳定心绞痛、术前心源性休克、术前主动脉内球囊反搏使用、外周动脉疾病和肺动脉高压),术中血管升压药使用更多,体外循环时间更长。
- 多变量风险校正后,6% HES 130/0.4使用与AKI风险显著增加无关(校正OR 1.01,95%CI 0.71-1.46,P=0.91)。
- 倾向性评分匹配配对分析证实上述结果。
临床怎么用
- 心脏手术围术期使用6% HES 130/0.4时,本队列未显示AKI风险显著增加,但需结合患者个体情况谨慎评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Recent trials have shown hydroxyethyl starch (HES) solutions increase the risk of acute kidney injury (AKI) in critically ill patients. It is uncertain whether these adverse effects also affect surgical patients. We sought to determine the renal safety of modern tetrastarch (6% HES 130/0.4) use in cardiac surgical patients. METHODS: In this multicentre prospective cohort study, 1058 consecutive patients who underwent cardiac surgery from 15th September 2012 to 15th December 2012 were recruited in 23 Spanish hospitals. RESULTS: We identified 350 patients (33%) administered 6% HES 130/0.4 intraoperatively and postoperatively, and 377 (36%) experienced postoperative AKI (AKI Network criteria). In-hospital death occurred in 45 (4.2%) patients. Patients in the non-HES group had higher Euroscore and more comorbidities including unstable angina, preoperative cardiogenic shock, preoperative intra-aortic balloon pump use, peripheral arterial disease, and pulmonary hypertension. The non-HES group received more intraoperative vasopressors and had longer cardiopulmonary bypass times. After multivariable risk-adjustment, 6% HES 130/0.4 use was not associated with significantly increased risks of AKI (adjusted odds ratio 1.01, 95% CI 0.71-1.46, P=0.91). These results were confirmed by propensity score-matched pairs analyses. CONCLUSIONS: The intraoperative and postoperative use of modern hydroxyethyl starch 6% HES 130/0.4 was not associated with increased risks of AKI and dialysis after cardiac surgery in our multicentre cohort.
引用
- Vives M, Callejas R, Duque P, et al. Modern hydroxyethyl starch and acute kidney injury after cardiac surgery: a prospective multicentre cohort. Br J Anaesth. 2016. PMID: 28077532. doi:10.1093/bja/aew258
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。